The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients

The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients

Background: Anti-programmed cell death 1 (PD-1) monoclonal antibodies (Abs) unleash an immune response to cancer. However, a disruption of the immune checkpoint function by blocking PD-1/PD-ligand 1(PD-L1) signaling may trigger myasthenia gravis (MG) as a life-threatening immune-related adverse even...

Full description

Bibliographic Details
Main Authors: Koichi Saruwatari, Ryo Sato, Shunya Nakane, Shinya Sakata, Koutaro Takamatsu, Takayuki Jodai, Remi Mito, Yuko Horio, Sho Saeki, Yusuke Tomita, Takuro Sakagami
Format: Article
Language:English
Published: MDPI AG 2019-01-01
Series:Cancers
Subjects:
anti-PD-1 monoclonal antibodies
anti-acetylcholine receptor (AChR) antibody
B cell
immune checkpoint blockade
immune-related adverse events (irAEs)
myasthenia gravis (MG)
non-small-cell lung cancer (NSCLC)
nivolumab
programmed cell death ligand 1 (PD-L1)
T cell
Online Access:https://www.mdpi.com/2072-6694/11/2/140

Internet

https://www.mdpi.com/2072-6694/11/2/140

Similar Items